Sanofi-aventis (SNY) and Regeneron (REGN) Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients
Tweet Send to a Friend
Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that advanced ovarian cancer patients with recurrent symptomatic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
